LlLLY/BOEHRINGER MANNHEIM DIABETES CO-PROMOTION ALLIANCE
Executive Summary
LlLLY/BOEHRINGER MANNHEIM DIABETES CO-PROMOTION ALLIANCE agreement in principle will focus in the U.S. on co-promotion of B-M's Accu-Chek blood glucose monitoring devices and Lilly's Humulin insulin products, which are estimated to be a $600 mil. to $620 mil. sales franchise. Sales forces are currently being trained on both products with the goal of integrating insulin and glucose monitoring therapies, B-M reported. Lilly said sales reps are already co-promoting the products in the field.